Telomir Pharmaceuticals, Inc.
TELO
$1.50
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.89M | 10.75M | 10.01M | 8.25M | 3.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.17M | 12.57M | 12.30M | 10.48M | 5.42M |
| Operating Income | -16.17M | -12.57M | -12.30M | -10.48M | -5.42M |
| Income Before Tax | -16.14M | -12.52M | -16.59M | -23.02M | -18.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.14 | -12.52 | -16.59 | -23.02 | -18.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.14M | -12.52M | -16.59M | -23.02M | -18.74M |
| EBIT | -16.17M | -12.57M | -12.30M | -10.48M | -5.42M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.54 | -0.42 | -0.57 | -0.82 | -0.68 |
| Normalized Basic EPS | -0.34 | -0.26 | -0.36 | -0.34 | -0.25 |
| EPS Diluted | -0.54 | -0.42 | -0.57 | -0.82 | -0.68 |
| Normalized Diluted EPS | -0.34 | -0.26 | -0.36 | -0.34 | -0.25 |
| Average Basic Shares Outstanding | 119.04M | 118.64M | 116.65M | 114.09M | 111.57M |
| Average Diluted Shares Outstanding | 119.04M | 118.64M | 116.65M | 114.09M | 111.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |